These anti-androgen drugs have been shown to be effective and safe for the treatment of prostate cancer for decades, and are promising for mitigating symptom severity in patients with SARS-CoV-2 by downregulating TMPRSS2 levels. This evidence concerns the gene TMPRSS2 and prostate cancer.